Proactive Investors - Run By Investors For Investors

Paradigm Biopharmaceuticals director buys shares on-market

The company has today commenced the retail component of its $77.9 million capital raising.
man with briefcase running up ascending share price arrow
The non-executive director purchased the shares at an average price of $1.647

Paradigm Biopharmaceuticals Ltd (ASX:PAR) non-executive director Christopher Fullerton has purchased $32,130 worth of shares through on-market trades.

The 19,500-share purchase at an average price of $1.647 increases his overall holding to 855,500 shares.

Notably, this purchase price was done at a premium to the recent capital raising offer price of $1.50.

READ: Paradigm Biopharmaceuticals secures $61.3 million in first stage of raising

The capital raising will raise $77.9 million and comprised of a $61.3 million institutional component, which is complete, and a $16.6 million retail component which opens today.

Paradigm’s chairman Graeme Kaufman said in a letter to shareholders earlier this week: “It is anticipated that they will be applied, in conjunction with the Placement funds, to fund the company’s osteoarthritis and MPS (rare disease) programs through to end of their pivotal phase 3 studies, new drug applications, working capital, costs of offer, further preclinical studies and possibly further intellectual property acquisitions.”

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

1538160791_petri-dishes.jpg
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
researcher at microscope
May 25 2019
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use